These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29061943)

  • 41. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma.
    Aust DE; Haase M; Dobryden L; Markwarth A; Löhrs U; Wittekind C; Baretton GB; Tannapfel A
    Int J Cancer; 2005 Jul; 115(5):673-7. PubMed ID: 15704157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF in malignant melanoma progression and metastasis: potentials and challenges.
    Alqathama A
    Am J Cancer Res; 2020; 10(4):1103-1114. PubMed ID: 32368388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
    Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
    Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.
    Sumimoto H; Miyagishi M; Miyoshi H; Yamagata S; Shimizu A; Taira K; Kawakami Y
    Oncogene; 2004 Aug; 23(36):6031-9. PubMed ID: 15208655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
    Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
    Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.
    Riemer P; Sreekumar A; Reinke S; Rad R; Schäfer R; Sers C; Bläker H; Herrmann BG; Morkel M
    Oncogene; 2015 Jun; 34(24):3164-75. PubMed ID: 25109331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAF mutation testing in clinical practice.
    Ziai J; Hui P
    Expert Rev Mol Diagn; 2012 Mar; 12(2):127-38. PubMed ID: 22369373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The MAPK pathway in melanoma.
    Fecher LA; Amaravadi RK; Flaherty KT
    Curr Opin Oncol; 2008 Mar; 20(2):183-9. PubMed ID: 18300768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating
    Yu Y; Wang X; Li Q; Zhang M; Xu P; Chen Y; Yan Y; Zhang L
    Oncol Lett; 2018 Jan; 15(1):635-641. PubMed ID: 29387237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
    Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
    ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.